Cipla Ltd ((IN:CIPLA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cipla Ltd. has recently completed a clinical study titled To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients. The study aimed to demonstrate the pharmacodynamic bioequivalence of a test inhalation aerosol to a reference product in patients with stable mild asthma, highlighting its significance in providing alternative treatment options.
The intervention involved testing Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) against a placebo and two reference products, Ventolin HFA, to assess their bronchoprotective effects in asthma patients.
The study was designed as a randomized, double-blind, crossover trial focusing on treatment. Participants and investigators were masked to ensure unbiased results.
The study commenced on December 6, 2023, with its primary completion and last update submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and data availability.
The completion of this study could potentially enhance Cipla’s market position by validating their product’s efficacy, possibly influencing stock performance positively. It also adds competitive pressure in the asthma treatment market, dominated by established brands like Ventolin.
The study is now completed, with further details accessible on the ClinicalTrials portal.